CARE™ Needs Assessment: Innovation and Access in Rheumatic Diseases

1.) Biologic and targeted synthetic therapy has drastically improved patient outcomes in RD over the last two decades.

2.) I am satisfied with the current therapy options available for my patients with RD.

3.) Having access to biologic and targeted synthetic treatment is important to my patients.

4.) Acquisition cost is only one component of overall cost benefit of biologic and targeted synthetic therapies.

5.) Access to patient support programs (PSPs) is important to my patients.

6.) Patient reported outcomes (PROs) are a very important consideration for making RD treatment decisions.

7.) PSPs are invaluable to me in my practice, and to my health care team.

8.) I generally aim to achieve clinical remission for my patients.

9.) With current therapy options available, my patients generally reach clinical remission as defined by validated indices such as DAS-28 CRP, CDAI, or SDAI.

10.) New innovative biologic therapies will provide greater benefits to patients than current biologic therapies.

11.) New targeted synthetic therapies will provide greater benefits to patients than current biologic therapies.

12.) Targeted synthetic therapies have the potential to raise the standard of care in terms of achieving remission.